Chronic kidney disease measures for cardiovascular risk prediction

Mok, Yejin; Ballew, Shoshana H.; Matsushita, Kunihiro

doi:10.1016/j.atherosclerosis.2021.09.007

Cited by 22 publications

(15 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-traditional factors linked to mineral and vitamin D metabolism can clarify the reason for the increased CVD risk in CKD, with vascular calcification as the underlying mechanism [40]. CKD-induced changes exacerbate inflammation and oxidative stress, leading to vascular alterations, including atherosclerosis, arterial stiffness, and calcification, as well as other abnormalities that raise the risk of CVD [8, 41]. Consequently, cancer patients should heed non-traditional CVD risk factors, such as low eGFR and CKD.…”

Section: Discussionmentioning

confidence: 99%

Association of Chronic Kidney Disease with Cardiovascular Disease in Cancer Patients: A Cross-Sectional Study

Liu,

Zhang,

Meng

et al. 2023

Cardiorenal Med

View full text Add to dashboard Cite

Introduction: Due to the cardiotoxicity of cancer treatment and traditional risk factors for cardiovascular disease (CVD) such as obesity, diabetes, dyslipidemia, and hypertension, cancer patients are at higher risk of developing CVD. However, limited research exists on the correlation between chronic kidney disease (CKD) and CVD risk in cancer patients. Methods: This cross-sectional study selected cancer patients aged ≥20 years from the National Health and Nutrition Examination Survey (NHANES) conducted from 2015 to 2020. Multivariable logistic regression was used to assess the association between CKD and CVD in cancer patients. Additionally, subgroup analyses were conducted to investigate the association among different groups of cancer patients. Results: We included 1700 adult cancer patients (52.53% were female). After multivariable adjustment for covariates including traditional CVD factors, CKD was significantly associated with CVD, with an odds ratio (95% confidence interval) and P-value of 1.61(1.18,2.19) and 0.004. Subgroup analyses after multivariable adjustment showed a significant correlation between CKD and increased CVD risk in the following populations: age ≥60 years, males, White ethnicity, and individuals with or without traditional CVD factors (obesity, diabetes, dyslipidemia, and hypertension). Conclusions: CKD remains a significant factor in the higher risk of CVD among adult cancer patients in the United States, even after adjustment for traditional CVD risk factors. Therefore, to reduce the risk of CVD in cancer patients, it is important to treat CKD as a non-traditional risk factor for CVD and actively manage it.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of Chronic Kidney Disease with Cardiovascular Disease in Cancer Patients: A Cross-Sectional Study

Liu,

Zhang,

Meng

et al. 2023

Cardiorenal Med

View full text Add to dashboard Cite

show abstract

“…CKD frequently causes lipid disturbances and an increased risk of cardiovascular disease (CVD) [ 27 ]. Hypertension is not only a major risk factor for CVD, but also a common cause of CKD [ 27 , 28 ]. CKD is also a complication of hypertension [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

Risk prediction of the progression of chronic kidney disease stage 1 based on peripheral blood samples: construction and internal validation of a nomogram

Wu,

Zhou,

et al. 2023

Renal Failure

View full text Add to dashboard Cite

Patients with chronic kidney disease (CKD) have high morbidity and mortality, and the disease progression has a significant impact on their survival and living standards. This research aims to analyze risk factors for CKD stage 1 and provide a reference for clinical decision making. The clinical data and peripheral blood samples of 300 patients with CKD stage 1 were collected retrospectively. Patients were randomly assigned into a training set ( n = 210) and a validation set ( n = 90). Patients’ baseline characteristic levels were subjected to statistical tests for difference. Univariate and multivariate Cox regression analyses were utilized to identify risk factors influencing disease progression. Subsequently, a prediction model for disease progression was developed using a nomogram, and the model’s accuracy was assessed using the C-index and calibration curve. The results revealed that hypertension, diabetes, and urinary albumin were essential factors in the progression of CKD stage 1. The nomogram was constructed and then the C-index was calculated. The calibration curve was utilized to assess the risk model. The C-index of the training set was 0.75, and the C-index of the validation set was 0.73, suggesting a good predictive ability of the model. The risk model accurately predicted the progression of CKD stage 1, which is of great significance to developing personalized treatment for patients in clinical practice.

show abstract

“…It's a feature that patients with CKD always have a high morbidity of non-atherosclerotic heart diseases, and the condition worsens as the dialysis frequency increased [6]. And in turn, the coexistence of CV disease could further raise the mortality risk in patients with CKD [7,8]. Given the devastating effects of this disease, effective strategies to slow the progression of CKD and provide cardiovascular protection are always urgently demanded.…”

Section: Introductionmentioning

confidence: 99%

Cardiorenal effects of sodium glucose cotransporter 2 inhibitors in patients with diabetic and non-diabetic chronic kidney disease: A system review and meta-analysis

Zhou

Zhang

Huang

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose To estimate the cardiorenal benefits and safety outcomes of SGLT-2 inhibitors in chronic kidney disease patients with and without diabetes. Methods We did a systematic review and meta-analysis of randomized, placebo-controlled, cardiovascular and kidney outcome trials of SGLT-2 inhibitors in patients diagnosed with chronic kidney disease (CKD). PubMed, Embase and Cochrane library database were searched for eligible studies published up to March 10, 2023. The RoB 2.0 tool was utilized to assess the bias risk of the enrolled trials. Review Manager (version 5.3) was used for meta‐analysis. Results Four RCTs encompassing 21,031 participants with CKD were enrolled, and 4,967 of whom had no history of diabetes at randomization. Pooled analyses demonstrated that SGLT-2 inhibitors were associated with reduced risk of cardiorenal outcomes in CKD patients with diabetes (RR = 0.70, 95% CI: 0.64–0.77, p < 0.001), and reduced the risk of progression of nephropathy in CKD patients without diabetes (RR = 0.70, 95% CI: 0.49–0.99, p = 0.04). Conclusions Current evidences suggest that SGLT-2 inhibitors reduce the cardiorenal risk in CKD patients with diabetes, and nephroprotective effects of SGLT-2 inhibitors were identified in CKD patients without diabetes. Protocol registration: This review is registered in prospective register of systematic reviews (PROSPERO CRD42023404821).

show abstract

Chronic kidney disease measures for cardiovascular risk prediction

Cited by 22 publications

References 121 publications

Association of Chronic Kidney Disease with Cardiovascular Disease in Cancer Patients: A Cross-Sectional Study

Association of Chronic Kidney Disease with Cardiovascular Disease in Cancer Patients: A Cross-Sectional Study

Risk prediction of the progression of chronic kidney disease stage 1 based on peripheral blood samples: construction and internal validation of a nomogram

Cardiorenal effects of sodium glucose cotransporter 2 inhibitors in patients with diabetic and non-diabetic chronic kidney disease: A system review and meta-analysis

Contact Info

Product

Resources

About